Recent clinical trials exploring the use of ICIs, including monoclonal antibodies, as antagonists of PD-1 or PD-L1 receptors have shown significant improvement in the survival rate of patients with advanced non-small-cell lung cancer (NSCLC) [16, 17]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.